Siemens Healthineers has launched Accela, a new radiotherapy solution engineered around its NeoArc dynamic modulated arc therapy technology, with the system designed to deliver faster stereotactic treatments while improving treatment planning and workflow efficiency for cancer centers.
Accela is currently 510(k) pending and is not available for sale in any market, meaning commercialization and final feature availability remain subject to regulatory clearance.
The system is designed around NeoArc dynamic modulated arc therapy, or DMAT, a new radiation oncology technique that combines a faster rotating gantry, multi-leaf collimator, and higher dose rate to create conformal treatment plans while reducing treatment delivery times.
Siemens Healthineers said Accela can support single breath-hold stereotactic treatments and enable multi-site stereotactic body radiation therapy, or SBRT, in as little as 60 seconds.
The shorter delivery time is intended to reduce how long patients remain on the treatment table, which can be particularly important for individuals who have difficulty remaining still or holding their breath during treatment.
Accela also incorporates advanced AI and treatment-planning algorithms designed to help clinicians balance plan quality with delivery speed.
The company said the platform includes the largest HyperSight cone-beam CT imaging panel, alongside a newly designed multi-leaf collimator, high-speed gantry rotation of 2.5 revolutions per minute, dose rates of up to 40 Gy per minute, and a new eight-megavolt flattening filter-free energy setting.
These capabilities are intended to support faster and more precise radiation delivery across a broad range of treatment cases.
Siemens Healthineers is positioning Accela as a response to several challenges facing oncology providers, including rising cancer volumes, increasingly complex treatment requirements, and healthcare staffing constraints.
By shortening both treatment delivery and planning times, the company believes the system can make more sophisticated radiotherapy techniques practical for a broader range of cancer centers.
The platform was developed through several years of collaboration between Siemens Healthineers and an advisory group of major cancer research institutions.
Participating organizations included Mayo Clinic, Washington University School of Medicine in St. Louis and Siteman Cancer Center, University Hospital Zurich, Seidman Cancer Center at University Hospitals Cleveland Medical Center, Maastro – Maastricht Radiation Oncology Institute, Mass General Brigham Cancer Institute, and Memorial Sloan Kettering Cancer Center.
Siemens Healthineers said clinical input, product evaluations, and research collaborations with these institutions helped guide the development of Accela and NeoArc.
The technology is being introduced through Varian, Siemens Healthineers’ cancer-care business, which develops radiation oncology systems and related treatment technologies.
Accela represents the latest effort by Siemens Healthineers to integrate medical imaging, artificial intelligence, software, and radiation therapy into a more unified cancer treatment platform.
The company said the architecture behind the system reflects approximately eight years of development, building on its existing imaging capabilities, radiation oncology installed base, clinical relationships, and AI software.
The launch also reflects a broader industry push toward reducing the time required for complex radiotherapy while maintaining treatment precision.
Stereotactic radiotherapy typically involves delivering highly focused radiation doses to precisely defined targets, making treatment planning, patient positioning, and delivery accuracy particularly important.
By increasing delivery speed, Siemens Healthineers is seeking to reduce treatment times without sacrificing the precision required for these procedures.
The company also sees potential for faster radiotherapy delivery to improve the scalability of advanced treatment methods.
Cancer centers dealing with higher patient volumes could potentially perform sophisticated treatments more efficiently if treatment sessions require less time, although the practical impact will depend on clinical adoption, workflow integration, regulatory clearance, and individual patient requirements.
Siemens Healthineers operates in more than 180 countries, with direct representation in more than 70.
The company generated approximately €23.4 billion in revenue during fiscal 2025 and employed about 74,000 people worldwide. Its major businesses include medical imaging, diagnostics, cancer care, minimally invasive therapies, digital healthcare technology, and artificial intelligence.
KEY QUOTES:
“Accela is the kind of leap our field doesn’t see often. It’s faster, it’s built on a fundamentally modern architecture, and it introduces a generational shift in treatment planning. But what excites me most is its potential to alter the biological response to radiotherapy. That’s not incremental progress; it’s a new chapter.”
Dee Khuntia, MD, Chief Medical Officer At Varian
“Today’s announcement shows a level of innovation in radiotherapy only Siemens Healthineers can deliver. It stands on a foundation that took decades to build: a global imaging business, our radiation-oncology installed base, mature AI and software, and long-term clinical relationships. We owe enormous gratitude to the thousands of colleagues whose work and ingenuity over the past eight years have brought us here.”
Arthur Kaindl, Head Of Varian
